HalioDx

The company will use the money to continue development of its flagship Immunoscore colon cancer assay, among other things.

Companies are now expected to have their tests cleared by authorities for clinical use, and to bring their entire catalogs into line with the new regulations by May 2022.

The partners will jointly develop and commercialize gene expression assays to predict response to cancer immunotherapy, based on the nCounter platform.

The firm, HalioDx, was formed following the departure of Qiagen Marseille's executive team and all its employees. 

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.